Project Description

Imatinib (Glivec), a potent inhibitor of the constitutively activated Abl tyrosine kinase domain in the Bcr-Abl oncoprotein, shows remarkable clinical activity in patients of chronic myelogenous leukemia (CML).

Reference:

1. Cowan-Jacob, S. W. et al. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta crystallographica. Section D, Biological crystallography 63, 80-93, doi:10.1107/S0907444906047287 (2007).